An Open Label Phase Ib/II Study of Trastuzumab Deruxtecan (T-Dxd) in Combination with Nivolumab and CAPOX for Patients with HER2-low Expressing Gastroesophageal Adenocarcinoma (EPOC2203)
ANNALS OF ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined